EMA Recommends Dupixent Approval for Children with Chronic Urticaria
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy SNY?
Source: seekingalpha
- Pediatric Indication Expansion: The European Medicines Agency's Committee recommends approval of Sanofi and Regeneron's Dupixent (dupilumab) for treating chronic spontaneous urticaria in children aged 2 to 11, marking a significant expansion in the drug's pediatric indications, which is expected to substantially boost market demand and sales.
- Clinical Trial Support: This recommendation is supported by data from the phase 3 LIBERTY-CUPID program, demonstrating Dupixent's efficacy against chronic spontaneous urticaria, further solidifying its position in the treatment landscape and likely attracting more prescriptions from healthcare providers.
- Existing Approval Status: Dupixent is already approved for chronic spontaneous urticaria in individuals aged 12 and older, and the expansion into pediatric indications will enable it to capture a larger share of the competitive market, enhancing the companies' influence in the pediatric pharmaceutical sector.
- Optimistic Market Outlook: With the application of Dupixent in the pediatric population, it is anticipated to drive long-term growth for both Sanofi and Regeneron, especially against the backdrop of rising demand for allergy-related medications, thereby further enhancing their competitiveness in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 44.350
Low
57.00
Averages
79.36
High
119.07
Current: 44.350
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dianthus Therapeutics Early Decision Boosts Stock Surge
- Early Decision Impact: Dianthus Therapeutics announced an early 'go' decision for its experimental drug claseprubart in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19% surge in stock price on Monday, reflecting heightened market optimism.
- Clinical Trial Results: In part A of the trial, more than 20 responders were confirmed out of 40 participants, achieving a response rate of 50% or greater, with no serious infections or discontinuations observed, indicating both safety and efficacy of the drug.
- Analyst Rating Upgrades: Truist raised Dianthus's price target from $63 to $110, while H.C. Wainwright increased its target from $47 to $130, also boosting the probability of launch for claseprubart from 26% to 35%, showcasing confidence in the drug's prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around DNTH stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor interest in the company.
See More
Dianthus Achieves Key Milestones in CIDP Trial
- Trial Progress: Dianthus confirmed achieving the GO criteria with 20 confirmed responders in the open-label Part A of the trial, with fewer than 40 planned participants, indicating preliminary efficacy and potential market prospects for the treatment.
- Patient Recruitment Plan: The company expects to enroll up to 256 patients in Part A and randomize 128 patients in Part B, aiming to optimize trial design and enhance the reliability of clinical data.
- Strong Financial Position: As of December 31, 2025, Dianthus has $514.4 million in cash, providing runway into 2028, which bolsters investor confidence in its long-term growth potential.
- Robust Stock Performance: Dianthus shares have increased by 167.87% over the past 12 months, currently trading at $80.06, reflecting strong market performance and positive investor sentiment.
See More
Sanofi Sells Medley to EMS for Over $500M
- Expected Transaction Value: Sanofi has agreed to sell its generic drugmaker Medley to Brazilian pharmaceutical company EMS for over $500 million, although the exact figure remains undisclosed, which will significantly enhance EMS's competitive position in the Brazilian market.
- Market Share Increase: EMS Vice President Marcus Sanchez indicated that the acquisition is expected to boost EMS's market share in generics to approximately 30%, strengthening its market position while avoiding regulatory scrutiny.
- Completion Timeline: The deal is anticipated to close by the end of this year, pending approval from Brazil's antitrust authority, Cade, with Sanofi continuing to manage Medley until the transaction is finalized to ensure business continuity.
- Historical Context: Sanofi acquired Medley in 2009 for $665 million when it was the third-largest pharmaceutical company in Brazil with over 1,500 employees, marking a significant strategic shift for Sanofi in the Brazilian market.
See More
Sanofi Partners with Sino Biopharmaceutical in $1.53bn Licensing Deal
- Licensing Agreement Details: Sanofi's licensing agreement with Sino Biopharmaceutical is valued at up to $1.53 billion, including an upfront payment of $135 million, indicating strong confidence in Sino's first-in-class anti-inflammatory and anti-fibrotic asset, rovadicitinib.
- Market Potential: Rovadicitinib is marketed in China under the brand name Anxu and was initially approved for treating three types of rare bone marrow cancers, which is expected to provide Sanofi with significant market opportunities in chronic graft versus host disease (cGVHD).
- Clinical Trial Progress: Sino is conducting a Phase III trial for rovadicitinib in China, expected to complete by October 2029, and has also secured approval for a Phase II study in the US, showcasing the drug's potential in GVHD treatment.
- Market Competition Analysis: With Imbruvica and Jakavi nearing the end of their market exclusivity, rovadicitinib is poised to fill this market gap, particularly in GVHD treatment, where 201 clinical trials are currently underway, highlighting the intense competition in this field.
See More
Sino Biopharmaceutical Licenses Blood Cancer Drug to Sanofi for Up to $1.53B
- Agreement Reached: Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has signed an exclusive licensing agreement with Sanofi for the blood cancer drug rovadicitinib, with a total deal value of up to $1.53 billion, highlighting Sino's strategic positioning in the global market.
- Upfront and Milestone Payments: Sino Biopharmaceutical is set to receive $135 million upfront, along with milestone payments that could reach $1.395 billion, reflecting the significant value of the drug's development and market potential.
- Royalty Structure: Chia Tai Tianqing will receive a tiered royalty of a double-digit percentage based on the annual net sales of rovadicitinib, which will provide a continuous revenue stream and enhance the company's financial stability.
- Drug Approval and Market Outlook: Rovadicitinib was approved by Chinese regulators last month as a first-line treatment for adults with a rare blood cancer, and the U.S. has also approved mid-stage trials for chronic graft-versus-host disease, indicating a promising international market outlook for the drug.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
Dianthus Therapeutics Early Decision Boosts Stock Surge
- Early Decision Impact: Dianthus Therapeutics announced an early 'go' decision for its experimental drug claseprubart in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19% surge in stock price on Monday, reflecting heightened market optimism.
- Clinical Trial Results: In part A of the trial, more than 20 responders were confirmed out of 40 participants, achieving a response rate of 50% or greater, with no serious infections or discontinuations observed, indicating both safety and efficacy of the drug.
- Analyst Rating Upgrades: Truist raised Dianthus's price target from $63 to $110, while H.C. Wainwright increased its target from $47 to $130, also boosting the probability of launch for claseprubart from 26% to 35%, showcasing confidence in the drug's prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around DNTH stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor interest in the company.
See More
Dianthus Achieves Key Milestones in CIDP Trial
- Trial Progress: Dianthus confirmed achieving the GO criteria with 20 confirmed responders in the open-label Part A of the trial, with fewer than 40 planned participants, indicating preliminary efficacy and potential market prospects for the treatment.
- Patient Recruitment Plan: The company expects to enroll up to 256 patients in Part A and randomize 128 patients in Part B, aiming to optimize trial design and enhance the reliability of clinical data.
- Strong Financial Position: As of December 31, 2025, Dianthus has $514.4 million in cash, providing runway into 2028, which bolsters investor confidence in its long-term growth potential.
- Robust Stock Performance: Dianthus shares have increased by 167.87% over the past 12 months, currently trading at $80.06, reflecting strong market performance and positive investor sentiment.
See More
Sanofi Sells Medley to EMS for Over $500M
- Expected Transaction Value: Sanofi has agreed to sell its generic drugmaker Medley to Brazilian pharmaceutical company EMS for over $500 million, although the exact figure remains undisclosed, which will significantly enhance EMS's competitive position in the Brazilian market.
- Market Share Increase: EMS Vice President Marcus Sanchez indicated that the acquisition is expected to boost EMS's market share in generics to approximately 30%, strengthening its market position while avoiding regulatory scrutiny.
- Completion Timeline: The deal is anticipated to close by the end of this year, pending approval from Brazil's antitrust authority, Cade, with Sanofi continuing to manage Medley until the transaction is finalized to ensure business continuity.
- Historical Context: Sanofi acquired Medley in 2009 for $665 million when it was the third-largest pharmaceutical company in Brazil with over 1,500 employees, marking a significant strategic shift for Sanofi in the Brazilian market.
See More
Sanofi Partners with Sino Biopharmaceutical in $1.53bn Licensing Deal
- Licensing Agreement Details: Sanofi's licensing agreement with Sino Biopharmaceutical is valued at up to $1.53 billion, including an upfront payment of $135 million, indicating strong confidence in Sino's first-in-class anti-inflammatory and anti-fibrotic asset, rovadicitinib.
- Market Potential: Rovadicitinib is marketed in China under the brand name Anxu and was initially approved for treating three types of rare bone marrow cancers, which is expected to provide Sanofi with significant market opportunities in chronic graft versus host disease (cGVHD).
- Clinical Trial Progress: Sino is conducting a Phase III trial for rovadicitinib in China, expected to complete by October 2029, and has also secured approval for a Phase II study in the US, showcasing the drug's potential in GVHD treatment.
- Market Competition Analysis: With Imbruvica and Jakavi nearing the end of their market exclusivity, rovadicitinib is poised to fill this market gap, particularly in GVHD treatment, where 201 clinical trials are currently underway, highlighting the intense competition in this field.
See More
Sino Biopharmaceutical Licenses Blood Cancer Drug to Sanofi for Up to $1.53B
- Agreement Reached: Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has signed an exclusive licensing agreement with Sanofi for the blood cancer drug rovadicitinib, with a total deal value of up to $1.53 billion, highlighting Sino's strategic positioning in the global market.
- Upfront and Milestone Payments: Sino Biopharmaceutical is set to receive $135 million upfront, along with milestone payments that could reach $1.395 billion, reflecting the significant value of the drug's development and market potential.
- Royalty Structure: Chia Tai Tianqing will receive a tiered royalty of a double-digit percentage based on the annual net sales of rovadicitinib, which will provide a continuous revenue stream and enhance the company's financial stability.
- Drug Approval and Market Outlook: Rovadicitinib was approved by Chinese regulators last month as a first-line treatment for adults with a rare blood cancer, and the U.S. has also approved mid-stage trials for chronic graft-versus-host disease, indicating a promising international market outlook for the drug.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
